secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2026-05-21T21:16:19+00:00
Accession:  0001193125-26-234890
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk Therapeutics expands ADC pipeline with option for CPT113 in up to five new programs
--------------------------------------------------------------------------------

- Option agreement with Hangzhou DAC provides access to CPT113 for up to five internally developed ADC programs, including dual-payload variations.
- DXC006 data from Hangzhou DAC accepted for oral presentation at ASCO; J&J disclosed an ADC using CPT113 at AACR.
- PTK7-directed HWK-007 completed first dose cohort at 2 mg/kg, enrolling second cohort at 4 mg/kg; MUC16-directed HWK-016 enrolling first cohort at 2.5 mg/kg.
- Phase 1 dose-escalation data for HWK-007 and HWK-016 expected in first half of 2027; IND for HWK-206 anticipated mid-2026.
- Whitehawk retains global rights and full program control for new ADCs; anticipates IND submissions for multiple programs over next 12-24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/0001193125-26-234890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/d32951d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-234890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer